{
    "id": "7e66b440-6fcf-4a9d-92a0-33a783384d0c",
    "indications": {
        "text": "atomoxetine capsules selective norepinephrine reuptake inhibitor indicated treatment attention-deficit/hyperactivity disorder ( adhd ) . ( 1.1 )",
        "doid_entities": [
            {
                "text": "adhd (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "initial , target maximum daily dose ( 2.1 ) ( acute maintenance/extended treatment ) body weight initial daily dose target total daily dose maximum total daily dose children adolescents 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg children adolescents 70 kg adults 40 mg 80 mg 100 mg dosing adjustment \u2014 hepatic impairment , strong cyp2d6 inhibitor , patients known cyp2d6 poor metabolizers ( pms ) . ( 2.5 , 12.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "hypersensitivity atomoxetine constituents product . ( 4.1 ) atomoxetine capsules within 2 weeks discontinuing maoi drugs affect brain monoamine concentrations . ( 4.2 , 7.1 ) narrow angle glaucoma . ( 4.3 ) pheochromocytoma history pheochromocytoma . ( 4.4 ) severe cardiovascular disorders might deteriorate clinically important increases hr bp . ( 4.5 )",
    "ingredients": [
        {
            "name": "ATOMOXETINE HYDROCHLORIDE",
            "code": "57WVB6I2W0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_331697"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Rising Pharma Holdings, Inc.",
    "name": "Atomoxetine",
    "effectiveTime": "20250502",
    "indications_original": "Atomoxetine capsules are a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)",
    "contraindications_original": "Initial, Target and Maximum Daily Dose (2.1) (Acute and Maintenance/Extended Treatment) Body Weight Initial Daily Dose Target Total Daily Dose Maximum Total Daily Dose Children and adolescents up to 70 kg 0.5 mg/kg 1.2 mg/kg 1.4 mg/kg Children and\u00a0 adolescents over 70 kg and adults 40 mg 80 mg 100 mg Dosing adjustment \u2014 Hepatic Impairment, Strong CYP2D6 Inhibitor, and in patients known to be CYP2D6 poor metabolizers (PMs). ( 2.5 , 12.3)",
    "adverseReactions_original": "Hypersensitivity to atomoxetine or other constituents of product. (4.1) Atomoxetine capsules use within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. (4.2 , 7.1) Narrow Angle Glaucoma. (4.3) Pheochromocytoma or history of pheochromocytoma. (4.4) Severe Cardiovascular Disorders that might deteriorate with clinically important increases in HR and BP. ( 4.5 )",
    "drug": [
        {
            "name": "Atomoxetine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_127342"
        }
    ]
}